Clinical Trials Logo

Cognitively Normal clinical trials

View clinical trials related to Cognitively Normal.

Filter by:
  • None
  • Page 1

NCT ID: NCT06127667 Not yet recruiting - Cognitively Normal Clinical Trials

Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules. This study is not masked and its primary purpose is to develop a basic science understanding of the relationship between cerebrovascular health and balance control with aging. This study will involve 102 individuals classified as younger adults, middle-aged adults, and older adults who are neurotypical and cognitively normal. The primary outcome from a clinical trials perspective will be cerebrovascular response to a bout of aerobic exercise (i.e. change in cerebral blood flow with the performance of aerobic exercise on a recumbent stepper exercise machine). Non-interventional outcomes will be EEG measures of cortical activity and biomechanical kinetic and kinematic data recorded during standing balance reactions, as well as biological blood samples for genomic analysis.

NCT ID: NCT05456503 Recruiting - Alzheimer Disease Clinical Trials

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620

Start date: September 19, 2022
Phase: Phase 3
Study type: Interventional

The investigators will compare PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal seniors.

NCT ID: NCT03903211 Completed - Alzheimer Disease Clinical Trials

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Start date: April 9, 2019
Phase: Phase 2
Study type: Interventional

The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.